# Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

> **NCT01208168** · PHASE3 · TERMINATED · sponsor: **Promius Pharma, LLC** · enrollment: 468 (actual)

## Conditions studied

- Onychomycosis

## Interventions

- **DRUG:** NAB001
- **DRUG:** Vehicle alone

## Key facts

- **NCT ID:** NCT01208168
- **Lead sponsor:** Promius Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2013-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01208168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01208168, "Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01208168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*